Royalty Pharma (RPRX) Payables (2019 - 2026)

Royalty Pharma (RPRX) has 8 years of Payables data on file, last reported at $25.5 million in Q1 2026.

• For the quarter ending Q1 2026, Payables fell 32.28% year-over-year to $25.5 million; the trailing twelve-month figure through Mar 2026 stood at $25.5 million (down 32.28% YoY), and the FY2025 full-year result was $19.4 million, up 45.13% from the prior year.
• Payables advanced to $25.5 million in Q1 2026, from $19.4 million in the prior quarter.
• In the past five years, Payables ranged from a high of $41.4 million in Q3 2025 to a low of $5.8 million in Q2 2023.
• A 5-year average of $17.6 million and a median of $15.2 million in 2023 frame the typical range for Payables.
• Across the five-year window, Payables slumped 52.29% in 2023 and soared 303.1% in 2024, its largest moves.
• Tracing RPRX's Payables over 5 years: stood at $7.9 million in 2022, then soared by 91.82% to $15.2 million in 2023, then decreased by 11.84% to $13.4 million in 2024, then surged by 45.13% to $19.4 million in 2025, then surged by 31.33% to $25.5 million in 2026.
• Business Quant data shows RPRX's Payables at $25.5 million in Q1 2026, $19.4 million in Q4 2025, and $41.4 million in Q3 2025.